Vitronectin
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Vitronectin
| ||||||||||||||
| | ||||||||||||||
| The SMB domain (yellow) in complex with PAI-1 | ||||||||||||||
| Available structures: 1oc0, 1s4g, 1ssu | ||||||||||||||
| Identifiers | ||||||||||||||
| Symbol(s) | VTN; V75; VN; VNT | |||||||||||||
| External IDs | OMIM: 193190 MGI: 98940 Homologene: 532 | |||||||||||||
| ||||||||||||||
| RNA expression pattern | ||||||||||||||
| Orthologs | ||||||||||||||
| Human | Mouse | |||||||||||||
| Entrez | 7448 | 22370 | ||||||||||||
| Ensembl | ENSG00000109072 | ENSMUSG00000017344 | ||||||||||||
| Uniprot | P04004 | Q5SYG4 | ||||||||||||
| Refseq | NM_000638 (mRNA) NP_000629 (protein) | NM_011707 (mRNA) NP_035837 (protein) | ||||||||||||
| Location | Chr 17: 23.72 - 23.72 Mb | Chr 11: 78.32 - 78.32 Mb | ||||||||||||
| Pubmed search | [1] | [2] | ||||||||||||
Vitronectin is an abundant glycoprotein found in blood plasma and the extracellular matrix. Vitronectin has been speculated to be involved in hemostasis and tumor malignancy.
Structure
Vitronectin is a 75 kDa glycoprotein, consisting of 459 amino acid residues. About one third of the proteins molecular mass is composed of carbohydrates. Occasionally the protein is cleaved after arginine 379, to produce two chain vitronectin, where the two parts are linked by a disulfide bond. No high resolution structure has been determined experimentally yet.
The protein consists of three domains:
- The N-terminal Somatomedin B domain (1-39).
- A central domains with hemopexin homology (131-342).
- A C-terminal domain (residues 347-459) also with hemopexin homology.
Several structures has been reported for the Somatomedin B domain. Initially the protein was crystallized in complex with one of its physiological binding partners: the Plasminogen activator inhibitor-1 (PAI-1), and the structure solved for this complex. Subsequently two groups reported NMR structures of the domain. The Somatomedin B domain is a close knit disulfide knot, with 4 disulfide bonds within 35 residues. Different disulfide configurations had been reported for this domain but this ambiguity has been resolved by the crystal structure.
Homology models have been built for the central and C-terminal domains.
Biology
The Somatomedin B domain of Vitronectin binds to Plasminogen activator inhibitor-1 (PAI-1), and stabilizes it. Thus vitronectin serves to regulate proteolysis initiated by plasminogen activation. Additionally vitronectin is a component of platelets and is thus involved in hemostasis. Vitronectin contains an RGD (45-47) sequence which is a binding site for membrane bound integrins, e.g. the vitronectin receptor, which serve to anchor cells to the extra cellular matrix. The Somatomedin B domain interacts with the urokinase receptor, and this interaction has been implicated in cell migration and signal transduction. High plasma levels of both PAI-1 and the urokinase receptor have been shown to correlate with a negative prognosis for cancer patients. Cell adhesion and migration are directly involved in cancer metastasis, which provides a probable mechanistic explanation for this observation.
References
- ^ Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ (2003) How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration Nat Struct Biol. 2003 Jul;10(7):541-4 (full text article online: Entrez PubMed 12808446).
- ^ Kamikubo Y, De Guzman R, Kroon G, Curriden S, Neels JG, Churchill MJ, Dawson P, Oldziej S, Jagielska A, Scheraga HA, Loskutoff DJ, Dyson HJ. (2004) Disulfide bonding arrangements in active forms of the somatomedin B domain of human vitronectin. Biochemistry. 2004 Jun 1;43(21):6519-34 (full text article online: Entrez PubMed 15157085).
- ^ Mayasundari A, Whittemore NA, Serpersu EH, Peterson CB. (2004) The solution structure of the N-terminal domain of human vitronectin: proximal sites that regulate fibrinolysis and cell migration. J Biol Chem. 2004 Jul 9;279(28):29359-66. Epub 2004 Apr 30 (full text article online: Entrez PubMed 15123712).
- ^ Kamikubo Y, Okumura Y, Loskutoff DJ. (2002) Identification of the disulfide bonds in the recombinant somatomedin B domain of human vitronectin. J Biol Chem. 2002 Jul 26;277(30):27109-19. Epub 2002 May 17 (full text article online: Entrez PubMed 12019263).
- ^ Horn NA, Hurst GB, Mayasundari A, Whittemore NA, Serpersu EH, Peterson CB.(2004) Assignment of the four disulfides in the N-terminal somatomedin B domain of native vitronectin isolated from human plasma. J Biol Chem. 2004 Aug 20;279(34):35867-78. Epub 2004 Jun 1. (full text article online: Entrez PubMed 15173163).
- ^ Xu D, Baburaj K, Peterson CB, Xu Y (2001) Model for the three-dimensional structure of vitronectin: predictions for the multi-domain protein from threading and docking Proteins. 2001 Aug 15;44(3):312-20 (full text article online: Entrez PubMed 11455604).
- ^ Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ (2003) How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration Nat Struct Biol. 2003 Jul;10(7):541-4 (full text article online: Entrez PubMed 12808446).
- ^ Xu D, Baburaj K, Peterson CB, Xu Y (2001) Model for the three-dimensional structure of vitronectin: predictions for the multi-domain protein from threading and docking Proteins. 2001 Aug 15;44(3):312-20 (full text article online: Entrez PubMed 11455604).
External links
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

